Cabaletta Bio Statistics
Total Valuation
Cabaletta Bio has a market cap or net worth of $352.65 million. The enterprise value is $153.27 million.
| Market Cap | 352.65M |
| Enterprise Value | 153.27M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cabaletta Bio has 169.55 million shares outstanding. The number of shares has increased by 121.83% in one year.
| Current Share Class | 169.55M |
| Shares Outstanding | 169.55M |
| Shares Change (YoY) | +121.83% |
| Shares Change (QoQ) | +34.93% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 78.02% |
| Float | 141.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.79, with a Debt / Equity ratio of 0.12.
| Current Ratio | 5.79 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -80.94 |
Financial Efficiency
Return on equity (ROE) is -93.20% and return on invested capital (ROIC) is -52.74%.
| Return on Equity (ROE) | -93.20% |
| Return on Assets (ROA) | -48.19% |
| Return on Invested Capital (ROIC) | -52.74% |
| Return on Capital Employed (ROCE) | -85.56% |
| Weighted Average Cost of Capital (WACC) | 21.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 158 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.75% in the last 52 weeks. The beta is 3.26, so Cabaletta Bio's price volatility has been higher than the market average.
| Beta (5Y) | 3.26 |
| 52-Week Price Change | -14.75% |
| 50-Day Moving Average | 2.75 |
| 200-Day Moving Average | 2.91 |
| Relative Strength Index (RSI) | 35.57 |
| Average Volume (20 Days) | 6,259,293 |
Short Selling Information
The latest short interest is 33.33 million, so 19.66% of the outstanding shares have been sold short.
| Short Interest | 33.33M |
| Short Previous Month | 41.44M |
| Short % of Shares Out | 19.66% |
| Short % of Float | 23.55% |
| Short Ratio (days to cover) | 5.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -185.52M |
| Pretax Income | -181.32M |
| Net Income | -181.32M |
| EBITDA | -184.12M |
| EBIT | -185.52M |
| Earnings Per Share (EPS) | -$1.54 |
Balance Sheet
The company has $225.10 million in cash and $25.71 million in debt, with a net cash position of $199.39 million or $1.18 per share.
| Cash & Cash Equivalents | 225.10M |
| Total Debt | 25.71M |
| Net Cash | 199.39M |
| Net Cash Per Share | $1.18 |
| Equity (Book Value) | 210.59M |
| Book Value Per Share | 1.26 |
| Working Capital | 191.12M |
Cash Flow
In the last 12 months, operating cash flow was -$153.93 million and capital expenditures -$283,000, giving a free cash flow of -$154.21 million.
| Operating Cash Flow | -153.93M |
| Capital Expenditures | -283,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | -9.80M |
| Free Cash Flow | -154.21M |
| FCF Per Share | -$0.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cabaletta Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -121.83% |
| Shareholder Yield | -121.83% |
| Earnings Yield | -51.42% |
| FCF Yield | -43.73% |
Analyst Forecast
The average price target for Cabaletta Bio is $13.25, which is 537.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.25 |
| Price Target Difference | 537.02% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |